Premedication after grade 1 infusion reaction

Vantrexa · Metastatic NSCLC

MI-2026-0217RoutineArchivedWithin SLAEscalatedSafety

FAFatima Al-SayedMedical Information Lead

Restricted — potential adverse event

Access limited to Medical Information and Safety roles. Details are captured minimally and routed to pharmacovigilance per SOP-PV-014. AI features are disabled for this record (PRD §27.7).

Received: 17 Jan 2026, 07:27 UTC
Channel: Web portal
Requestor type: HCP
Country / region / team: France · Europe · MI Europe
Category: Safety
Response type: Custom response
Owner: FAFatima Al-Sayed
Due: 22 Jan 2026, 07:27 UTC
Responded: 20 Jan 2026, 18:27 UTC
Quality review: Passed
Related insight: —
Related standard response: None matched (topic-keyword match)

Workflow

12-stage inquiry workflow (PRD §16). Advancing records an audit event.

Received
Triage
Assigned
In progress
Escalated
Draft response
Medical review
Quality review
Sent
Follow-up required
Closed
12Archived

Current stageArchivedDemo action — not persisted

SLA

Routine: 120 h target · Routine 120 h / Urgent 48 h / Critical 24 h

SLA hours

120

Elapsed

83 h

to response

Remaining

37 h

69%

Timeline

17 Jan 2026, 07:27 UTC
Received via Web portal
HCP · France
17 Jan 2026, 07:27 UTC
Triage and assignment
Urgency Routine · assigned to MI Europe
17 Jan 2026, 07:27 UTC
Escalated
Safety flag — routed to pharmacovigilance
20 Jan 2026, 18:27 UTC
Response sent
Custom response · quality review passed
22 Jan 2026, 07:27 UTC
SLA due (120 h)

Draft response

Restricted record

AI suggestion disabled — safety-flagged inquiries are not interpreted by AI (PRD §27.7).

Draft response

Audit history

No audit events for this record

Create, update, approve and export events appear here with user, timestamp, previous and new values.

Data lineage: MI inquiry platform (IRMS, INT-05) · received 17 Jan 2026 · hourly sync.